spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:   gout 

 HSMN NewsFeed - 24 Jan 2024
ZWI Therapeutics, Inc. Announces a Series A Financing, Two Accomplished Biopharmaceutical CEOs Join the Board of Directors, and Appointment of Chief Executive Officer
Biopharmaceuticals Personnel Venture Capital
 HSMN NewsFeed - 6 Oct 2023
Amgen Completes Acquisition of Horizon Therapeutics plc
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Sep 2023
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Aug 2022
HemoShear Therapeutics Appoints Brian Wamhoff, PhD, Interim Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Mar 2022
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Trial Evaluating PRX-102 for the Treatment of Fabry Disease
Biopharmaceuticals
 HSMN NewsFeed - 24 Feb 2022
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission of a Marketing Authorization Application to the European Medicines Agency for PRX-102 for the Treatment of Fabry Disease
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 Dec 2021
HemoShear Therapeutics Appoints Patrick Horn, MD, PhD, Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Apr 2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Feb 2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease
Biopharmaceuticals
 HSMN NewsFeed - 11 Feb 2021
Protalix BioTherapeutics Enters into an Exclusive Partnership with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 28 Jul 2020
HemoShear Therapeutics Receives FDA Fast Track and Rare Pediatric Disease Designations for HST5040 to Treat Methylmalonic Acidemia and Propionic Acidemia
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 May 2020
Acquist Therapeutics Announces New Appointments to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 May 2020
Smith & Nephew launches new JOURNEY(TM) II Unicompartmental Knee System
Devices Orthopaedic Product Launch
 HSMN NewsFeed - 22 Apr 2020
FoRx Therapeutics AG Raises EUR 10 Million Seed Round and Becomes First Company to Develop a Pipeline of Drugs Targeting DNA Replication Stress for Cancer
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 21 Jan 2020
Astanza Laser Wins Marketing/PR Campaign Of The Year, Training Support Of The Year, And Customer Service Of The Year Awards At The 2019 MyFaceMyBody Global Aesthetic Awards
Devices Dermatology
 HSMN NewsFeed - 19 Jun 2019
HemoShear Therapeutics Names Biopharma Veteran Kathleen M. Metters, PhD, to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Nov 2018
Grünenthal Acquires Averitas Pharma and Establishes Commercial Footprint in the US
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 23 Apr 2018
Dr. Philip Just Larsen Appointed Chief Scientific Officer (CSO)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Feb 2018
Grünenthal Group Receives FDA's Expedited Access Pathway Designation for VIVO
Devices Surgery FDA
 HSMN NewsFeed - 15 Nov 2017
Noden Pharma Announces FDA Approval of Tekturna(R) (aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and Older
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 1 Sep 2017
Mark Fladrich Takes Office as the New CCO of the Grünenthal Group
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Oct 2016
Rigel Expands Leadership Team in Research and Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Apr 2016
Novartis Receives Three FDA Breakthrough Therapy Designations for IlaristTo Treat Rare Types of Periodic Fever Syndromes
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Sep 2015
Selecta Announces $38 Million Series E Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 8 Sep 2015
Selecta Biosciences Appoints Earl E. Sands, MD, as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Oct 2014
Selecta Announces More than $20 Million in Equity Funding
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 23 Jul 2013
Fred Cohen Appointed to BioCryst’s Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 May 2013
Novartis drug Ilaris(R) approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
Biopharmaceuticals. FDA
 HSMN NewsFeed - 9 May 2013
Cornerstone Therapeutics Acquires Exclusive U.S. Marketing Rights to PERTZYE(R) (pancrelipase) for Treatment of Exocrine Pancreatic Insufficiency in Patients With Cystic Fibrosis
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 5 Dec 2012
Savient Announces the Election of Robert G. Savage to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Nov 2012
BioCryst Pharmaceuticals and Presidio Pharmaceuticals Mutually Terminate Merger Transaction
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 19 Oct 2012
Savient Receives Positive CHMP Opinion for KRYSTEXXA(R) Approval in the EU
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Oct 2012
BioCryst Pharmaceuticals and Presidio Pharmaceuticals to Merge
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 24 Sep 2012
Savient Pharmaceuticals Names John P. Hamill Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Aug 2012
Pfizer Reports Results From Phase 3 Study Of Torisel (temsirolimus) In Combination With Bevacizumab In Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jun 2012
AstraZeneca Completes Acquisition of Ardea Biosciences
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 23 Apr 2012
AstraZeneca to Acquire Ardea Biosciences for $1.26 Billion Including Lead Product Lesinurad in Phase III Development for Gout
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 11 Apr 2012
Takeda to Acquire URL Pharma
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Mar 2012
Savient Announces Named Patient Programme for KRYSTEXXA(R) in the European Union for Patients with Refractory Chronic Gout
Biopharmaceuticals
 HSMN NewsFeed - 27 Jan 2012
U.S. Food And Drug Administration Approves Pfizer’s INLYTA(R) (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Jan 2012
Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA(R)
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 3 Nov 2011
Savient Pharmaceuticals Receives J-code for KRYSTEXXA(R)
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 6 Sep 2011
Savient Announces the Election of William F. Owen, Jr., M.D. and David Y. Norton to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jul 2011
Savient Pharmaceuticals Names Rheumatology Veteran Kenneth M. Bahrt, M.D. Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jun 2011
ZALTRAP (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 May 2011
BioCryst Pharmaceuticals Announces Appointment of Thomas Staab as Its Next Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 May 2011
FDA Approves INCIVEK(TM) (telaprevir) for People with Hepatitis C
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 May 2011
Teijin Pharma to Launch Feburic(r) (febuxostat) in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 29 Apr 2011
Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Apr 2011
FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 8 Apr 2011
Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 31 Mar 2011
VICTRELIS(TM) (boceprevir), Merck's Investigational Medicine, Added to Peginterferon Alfa-2a and Ribavirin Achieved Significantly Higher SVR Rates In Treatment-Failure Patients with Chronic HCV Genotype 1 Compared to Control
Biopharmaceuticals
 HSMN NewsFeed - 10 Mar 2011
Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Feb 2011
Savient Pharmaceuticals Announces Executive Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Jan 2011
Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Jan 2011
Savient Pharmaceuticals Provides Business Update
Biopharmaceuticals
 HSMN NewsFeed - 20 Dec 2010
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 15 Nov 2010
Christine A. Poon Elected to Regeneron Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 May 2010
Nuon Therapeutics Names Lee Rauch Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 May 2010
Abbott Receives FDA Approval for CREON(R) to Include Dosing Information for Patients With Chronic Pancreatitis and Pancreatectomy
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Apr 2010
FDA Approves New Drug Application for PANCREAZE(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Apr 2010
Ardea Biosciences, Inc. Announces Appointment of Stephen R. Davis as Executive Vice President and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Feb 2010
Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jan 2010
Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Nov 2009
Phase II/III Clinical Study Compares Safety and Efficacy of Two Doses of ZENPEP(TM) (Pancrelipase) Delayed-Release Capsules for Fat Absorption in Adult Chronic Pancreatitis Patients With Exocrine Pancreatic Insufficiency
Biopharmaceuticals
 HSMN NewsFeed - 19 Oct 2009
FDA Approves Colcrys(TM) (colchicine, USP) for Prevention of Gout Flares
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Oct 2009
FDA Advisory Committee Recommends Approval of PEGINTRON(R) for the Adjuvant Treatment of Stage III Malignant Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Aug 2009
Eurand Granted FDA Approval for ZENPEP(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Jul 2009
Allostera Pharma Inc. Closes $17M (CAD) Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 16 Jun 2009
FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout
Biopharmaceuticals
 HSMN NewsFeed - 12 Mar 2009
ULORIC(R) (febuxostat) 40-mg and 80-mg Tablets Now Available for the Chronic Management of Hyperuricemia in Patients with Gout
Biopharmaceuticals
 HSMN NewsFeed - 11 Mar 2009
FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Feb 2009
FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Jan 2009
Savient Announces FDA's Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Jan 2009
Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
Biopharmaceuticals
 HSMN NewsFeed - 31 Oct 2008
Savient Submits Biologics License Application (BLA) for pegloticase
Biopharmaceuticals
 HSMN NewsFeed - 31 Jul 2008
Javelin Pharmaceuticals and Baxter Healthcare Corporation Expand Commercial Supply Relationship for Anticipated Dyloject(TM) Global Growth
Biopharmaceuticals
 HSMN NewsFeed - 2 Jun 2008
Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 May 2008
Siemens Introduces Dual Energy Applications for General Imaging
Devices Radiology
 HSMN NewsFeed - 5 May 2008
Ipsen: Adenuric(R) (Febuxostat) Receives Marketing Authorisation in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 10 Mar 2008
Siemens Introduces New Dual Energy Applications to SOMATOM Definition
Devices Radiology
 HSMN NewsFeed - 10 Mar 2008
Javelin Pharmaceuticals' Dyloject Accepted by Scottish Medicines Consortium (SMC)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Feb 2008
Savient Provides Further Information on Top Line Phase 3 Trials Results for Puricase(R) (pegloticase)
Biopharmaceuticals
 HSMN NewsFeed - 21 Feb 2008
EMEA Recommends Marketing Authorisation of Ipsen's Adenuric(R) (Febuxostat) for the Treatment of Chronic Hyperuricaemia in Gout
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Dec 2007
New Drug Application for Tolvaptan, Otsuka's Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 14 Dec 2007
Javelin Pharmaceuticals Announces Successful Dyloject Pivotal US Phase 3 Trial Top-Line Results at New York City Analyst Day
Biopharmaceuticals
 HSMN NewsFeed - 13 Dec 2007
Puricase(R) (pegloticase) Meets Pre-Specified Primary Efficacy Endpoint in Two Replicate Phase 3 Studies
Biopharmaceuticals
 HSMN NewsFeed - 11 Dec 2007
Javelin Pharmaceuticals Launches Dyloject(R) in UK
Biopharmaceuticals
 HSMN NewsFeed - 26 Nov 2007
Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Oct 2007
Javelin Pharmaceuticals Receives Marketing Authorization Approval for Dyloject(R) in the United Kingdom
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 29 Oct 2007
Savient Pharmaceuticals Announces Appointment of New VP Manufacturing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Oct 2007
Savient Pharmaceuticals Completes Puricase(R) Phase 3 Studies for Treatment-Failure Gout
Biopharmaceuticals
 HSMN NewsFeed - 2 Aug 2007
FDA Issues Second Approvable Letter for Trexima(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Jul 2007
Victory Pharma, Inc. Doubling U.S. Sales Force
Biopharmaceuticals
 HSMN NewsFeed - 8 Jun 2007
Trexima(TM) (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
Biopharmaceuticals Neurology
 HSMN NewsFeed - 8 Jun 2007
Regeneron Submits Biologics License Application to U.S. FDA for IL-1 Trap (Rilonacept) for Treatment of CAPS
Biopharmaceuticals
 HSMN NewsFeed - 2 May 2007
Trexima(TM) (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across Multiple Migraine Attacks
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 May 2007
Trexima(TM) (Sumatriptan/Naproxen Sodium) Provided Relief of Both Traditional and Non-traditional Migraine Symptoms
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 Apr 2007
Advanced Magnetics Announces Positive Results from Two Additional Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement Therapeutic
Biopharmaceuticals
 HSMN NewsFeed - 26 Mar 2007
Victory Pharma, Inc. Sales Force Expansion Signifies Growth of Its US Commercial Operations
Biopharmaceuticals
 HSMN NewsFeed - 6 Mar 2007
Savient Announces Completion of Patient Enrollment in Phase 3 Trials of Puricase(R) for Treatment-Failure Gout
Biopharmaceuticals
 HSMN NewsFeed - 5 Jan 2007
Savient Pharmaceuticals Restructures Commercial Operations Following Launch of Authorized Generic
Biopharmaceuticals Generics
 HSMN NewsFeed - 3 Jan 2007
Victory Pharma, Inc. Signs NAPRELAN(R) Agreement; US Field Sales Force to Expand
Biopharmaceuticals Distribution
 HSMN NewsFeed - 3 Jan 2007
Hi-Tech Pharmacal Enters into Agreement with Victory Pharma, Inc. to Market and Distribute Naprelan(R)
Biopharmaceuticals Distribution
 HSMN NewsFeed - 29 Dec 2006
Savient Pharmaceuticals Announces Launch of Authorized Generic of Oxandrin(R) with Watson Pharmaceuticals
Biopharmaceuticals Generics
 HSMN NewsFeed - 12 Dec 2006
Savient Pharmaceuticals Announces Appellate Court Decision in Patent Infringement Lawsuit against Sandoz Pharmaceuticals and Upsher-Smith Laboratories
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 5 Dec 2006
Savient Pharmaceuticals Obtains Temporary Restraining Order in Patent Infringement Lawsuit Against Sandoz Pharmaceuticals and Upsher-Smith Laboratories
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 4 Dec 2006
Savient Pharmaceuticals Files Patent Infringement Lawsuit Against Sandoz Pharmaceuticals and Upsher-Smith Laboratories
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 9 Nov 2006
POZEN Submits Full Response to FDA Approvable Letter For Trexima(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Oct 2006
Ipsen: EMEA's Validation of Febuxostat's Marketing Authorization Application in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Sep 2006
Savient Pharmaceuticals Files Patent Infringement Lawsuit Against Barr Laboratories Inc.
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 20 Sep 2006
New Analysis Shows Patients Who Treat Their Migraine Pain Early With Trexima(TM) (Sumatriptan Succinate/Naproxen Sodium) Have Higher Sustained Pain-Free Rates Than Those Who Treat Late
Biopharmaceuticals
 HSMN NewsFeed - 20 Sep 2006
New Data Show Consistent Efficacy and Tolerability of Trexima(TM) (Sumatriptan Succinate/Naproxen Sodium) Across Multiple Migraine Attacks
Biopharmaceuticals
 HSMN NewsFeed - 20 Sep 2006
New Data Show Peak Concentration of Sumatriptan Occurred Earlier With Trexima(TM) (Sumatriptan Succinate/Naproxen Sodium) Compared to Imitrex(R) (Sumatriptan Succinate)
Biopharmaceuticals
 HSMN NewsFeed - 6 Jul 2006
Savient Appoints Chief Financial Officer and Treasurer
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 40

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 40 additional stories matching:
gout
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.